Market research
IMAB I-Mab
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 534M
- P/E ratio
- Not available
- Analyst target
- 8.6
- Dividend yield
- Not available
- Beta
- 1.46
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US44975P1030
- Market cap
- 534M
- P/E ratio
- Not available
- Analyst target
- 8.6
- Dividend yield
- Not available
- Beta
- 1.46
About
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IMAB discussion.
5 years, 4 months ago
I-Mab is currently in a long term uptrend where the price is trading 39.0% above its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.5.
Based on the above factors, I-Mab gets an overall score of 2/5.